CIK THERAPY FOR
GASTRIC CANCER
Clinical evidence, eligibility, and combination strategies for CIK cell therapy in gastric cancer โ supported by multiple randomised trials demonstrating improved survival and quality of life alongside standard chemotherapy.
analyticsAt a Glance
- check_circleMultiple RCTs confirm CIK + chemotherapy improves OS and PFS in gastric cancer over chemotherapy alone
- check_circleUsed post-resection, in locally advanced disease, and alongside first-line chemotherapy regimens
- check_circleQuality of life benefits are consistently reported alongside survival improvements
- check_circleCancerFax coordinates CIK therapy access at specialist gastric cancer centres in China
Why CIK Therapy Is Relevant in Gastric Cancer
Gastric cancer remains one of the leading causes of cancer death globally, with particularly high incidence across East Asia. Despite improvements in surgical technique and systemic chemotherapy, recurrence rates after resection remain high and second-line options in advanced disease are limited. CIK therapy addresses both post-surgical immune surveillance and systemic disease control as a chemotherapy combination partner.
โIn gastric cancer, where relapse after surgery remains the rule rather than the exception, CIK offers a sustained immune defence that chemotherapy alone cannot provide.โ
Post-Resection Adjuvant CIK
Following D2 gastrectomy, CIK therapy targets residual micro-disease that is invisible to post-operative imaging โ the primary driver of late recurrence. Multiple trials show improved disease-free survival with adjuvant CIK after curative resection.
CIK + First-Line Chemotherapy
The strongest evidence base combines CIK infusions with FOLFOX, XELOX, or SOX chemotherapy regimens in locally advanced or metastatic gastric cancer โ showing improved ORR, PFS, and OS versus chemotherapy alone in randomised trials.
HER2-Positive Gastric Cancer
For HER2-positive gastric cancer patients receiving trastuzumab-based therapy, CIK combination data is limited but biologically plausible โ antibody-dependent cellular cytotoxicity (ADCC) of trastuzumab may synergise with CIK cytotoxic mechanisms.
Quality of Life Preservation
Across multiple trials, patients receiving CIK alongside chemotherapy reported better appetite, reduced fatigue, and improved Karnofsky performance scores compared to chemotherapy alone โ a clinically meaningful benefit in a disease with significant treatment burden.
Clinical Efficacy Data: CIK in Gastric Cancer
Selected outcomes from randomised controlled trials of CIK therapy in gastric cancer. Data derived from published Chinese academic centre RCTs and systematic reviews.
CIK + Chemotherapy vs Chemotherapy Alone โ Overall Survival
Pooled 1-year OS data from Chinese RCTs comparing CIK + FOLFOX/XELOX vs chemotherapy alone in locally advanced/metastatic gastric cancer.
- 1-year OS (CIK + chemo)~70โ76%
- 1-year OS (chemo alone)~55โ62%
CIK + Chemotherapy vs Chemotherapy Alone โ Disease Control Rate
DCR (CR+PR+SD) comparison from multiple gastric cancer RCTs. Source: Systematic reviews of CIK gastric cancer trials, 2012โ2022.
- DCR (CIK + chemo)~78โ85%
- DCR (chemo alone)~63โ71%
Post-Resection Adjuvant CIK โ 3-Year DFS
3-year disease-free survival in post-gastrectomy patients receiving adjuvant CIK vs observation/chemotherapy alone. Source: Chinese adjuvant CIK trials.
- 3-year DFS (adjuvant CIK)~55โ65%
- 3-year DFS (control arm)~40โ50%
Gastric Cancer Patient Eligibility for CIK Therapy
CIK therapy applies across multiple gastric cancer treatment contexts. These parameters guide eligibility assessment at specialist centres.
| Patient Factor | CIK Eligibility | Notes |
|---|---|---|
| Post-D2 gastrectomy (Stage IIโIII, curative intent) | โ Good evidence | Adjuvant CIK reduces recurrence; initiate 3โ4 weeks post-surgery |
| Locally advanced โ first-line FOLFOX/XELOX/SOX | โ Strong evidence | Best-evidenced setting โ combination improves OS and DCR |
| Metastatic gastric cancer โ first-line | โ Evidence available | OS benefit demonstrated in combination RCTs |
| HER2-positive + trastuzumab-based therapy | โ Limited data | Biologically plausible combination; specialist consultation required |
| Post-second-line treatment (refractory) | โ Limited evidence | Some palliative evidence exists; clinical assessment required |
| Signet ring cell / diffuse-type gastric cancer | โ Limited data | Separate subgroup data is limited โ discuss with treating oncologist |
| ECOG PS โฅ3 or severe malnutrition | โ Generally excluded | Insufficient immune reserve for effective CIK manufacturing and activity |
CIK in Gastric Cancer โ Benefits vs Limitations
A balanced clinical view of what CIK therapy adds to gastric cancer management and where its evidence boundaries lie.
Benefits
- Survival benefit in combinationRCTs consistently show OS and PFS improvement when CIK is added to platinum-based doublet chemotherapy in locally advanced and metastatic gastric cancer.
- Compatible with all major chemo regimensCIK has been studied alongside FOLFOX, XELOX, SOX, and FLOT-equivalent regimens without significant additive toxicity.
- Quality of life improvementReduced fatigue, improved appetite, and better Karnofsky scores are consistently reported โ meaningful in a disease known for significant treatment burden.
- Post-surgical recurrence reductionAdjuvant CIK following curative gastrectomy addresses the high relapse risk that even optimal surgery and perioperative chemotherapy cannot eliminate.
Limitations
- Chinese trial predominanceThe evidence base is almost entirely from Chinese academic centres. Western guidelines (ESMO, NCCN) do not yet include CIK in gastric cancer recommendations.
- Limited HER2+ dataFor the growing proportion of gastric cancer patients receiving trastuzumab or trastuzumab deruxtecan, CIK-specific combination data is very limited.
- Requires multiple treatment cyclesSustained benefit requires 3โ6 CIK cycles over several months โ demanding sustained treatment commitment and repeated hospital visits.
- Variable response in diffuse-typeLauren diffuse-type and signet ring cell gastric cancers have distinct immune biology and limited CIK-specific subgroup data compared to intestinal type.
Gastric Cancer and CIK โ Key Numbers
Contextual figures that frame both the disease burden and the clinical impact of CIK therapy in gastric cancer.
- #5Global cancer incidence rank for gastric cancerGastric cancer disproportionately affects East Asian populations โ the same population where CIK evidence has been generated.
- +15โ18%Approximate 1-year OS improvement with CIK + chemo vs chemo aloneA meaningful absolute benefit in a disease where second-line options are limited and median OS with chemotherapy alone is 10โ14 months.
- 14โ21 daysCIK manufacturing time โ compatible with FOLFOX/XELOX cycle spacingCIK manufacturing fits within the 3-week rest interval between chemotherapy cycles, allowing seamless integration.
More from the CIK Cell Therapy Resource Library
Continue exploring CIK therapy โ from the patient introduction and manufacturing process to evidence in other cancers.
Frequently Asked Questions: CIK for Gastric Cancer
Can CIK therapy be used alongside trastuzumab for HER2-positive gastric cancer?
This is an area with limited but biologically interesting data. Trastuzumab kills HER2-overexpressing cancer cells partly via antibody-dependent cellular cytotoxicity (ADCC) โ a mechanism that involves NK cells, which share surface markers with CIK cells. This suggests a potential synergy, but clinical trial data for CIK + trastuzumab in HER2-positive gastric cancer is sparse. A specialist oncologist at the treating centre would need to assess this combination on a case-by-case basis.
When after gastrectomy should CIK therapy begin?
Most published protocols initiate blood collection for CIK manufacturing 3โ4 weeks after surgery, once the patient has recovered sufficient immune function and nutritional status. Manufacturing then takes 14โ21 days, meaning first infusion typically occurs 5โ7 weeks post-operatively. Your treating oncologist will determine timing based on your recovery, pathological staging, and whether adjuvant chemotherapy is also planned.
Can CIK therapy help with gastric cancer that has spread to the peritoneum?
Peritoneal metastasis from gastric cancer is one of the most challenging clinical scenarios. Systemic CIK therapy has limited direct efficacy against established peritoneal disease given the immunosuppressive peritoneal microenvironment. Some specialist centres in China are exploring intraperitoneal CIK delivery, but this remains investigational. CancerFax can identify centres conducting trials in this area for eligible patients.
How does CancerFax help gastric cancer patients access CIK therapy?
We begin by reviewing your complete gastric cancer records โ pathology (including Lauren classification and HER2 status), staging CT/PET imaging, surgical reports if applicable, and current or prior chemotherapy regimens. We prepare a structured oncology summary and identify the most appropriate specialist centre in China based on your disease profile. We then coordinate eligibility confirmation, treatment cost estimates, consultation scheduling, and logistics for your visit.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is CIK Therapy an Option for Your Gastric Cancer?
CancerFax reviews your gastric cancer records โ staging, histology, HER2 status, prior treatment, and surgical history โ and identifies whether CIK therapy in combination is appropriate for your case, then connects you with specialist centres in China.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.